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Neuroendocrineneoplasms(NENs)areadistinctiveentity,andnearly10%ofpatientsalreadyhavelivermetastasesatpresentation.
The management of neuroendocrine liver metastases (NEN-LM) is complex with diﬀering patterns of metastatic presentation. An
aggressiveapproachshouldbeusedtoresecttheprimarytumor,toremoveregionallymphnodes,andtoresectortreatappropriate
distant metastases (including liver tumors). Despite having an indolent course, NENs have a signiﬁcantly reduced survival when
liver metastases are untreated. Though a wide range of therapies are now available with a multimodal approach to the treatment,
surgical treatment oﬀers the only chance for a signiﬁcant survival prolongation and/or improvement of symptoms and quality of
life. A review of the existing surgical modalities for NEN-LM is discussed in this paper.
1.Introduction
Neuroendocrine tumors (NETs) consist of a group of neo-
plasms that arise from neuroendocrine cells dispersed
throughout the body and show variable clinical course. The
World Health Organization (WHO) classiﬁcations in 2000
and subsequently in 2004 did not address the diversity of
these tumors. A histologic grading system based on Ki-67
labelling index was proposed by the European Neuroen-
docrineTumourSociety(ENETS)[1,2].TheENETSgrading
system (G1, G2, G3) has thus been incorporated in the
new WHO 2010 classiﬁcation [3]. It is now recognized that
all neuroendocrine tumours are potentially malignant and
hence characterized as neuroendocrine neoplasms (NENs).
Intestinal NENs represent two-thirds [4], while pancreatic
NENs represent about one-third of gastroenteropancreatic
NENs (GEP-NENs) [5]. Besides regional lymph node
involvement, liver is the predominant site of metastases [6].
Up to 75% of patients with small bowel NEN and 30–85% of
pancreatic NENs present with liver metastases (NEN-LM)
either at initial evaluation or during the course of their
disease [7–9]. An additional 5–10% of NEN patients present
with liver metastases with unknown primary tumor site.
In contrast with the traditional opinion that NEN rep-
resents an indolent disease, Touzios et al. [10]r e p o r t e d5 -
year survivals range from 13–54% in patients with untreated
NEN-LM compared to 75–99% in those without liver metas-
tases [11–15].
2.LiverMetastases asaPrognostic Factor
Pancreatic NENs have a lower 5-year survival rate (30–60%)
compared to intestinal NENs (60–90%) [16–18]. Liver me-
tastases, however, are the most important prognosticator of
survival in patients with NEN regardless of the primary site
[19].
Two large population-based studies [7, 20] with 13715
and 4104 patients, reported that 12.9% of patients already
had liver metastases at initial diagnosis regardless of tumor
location and 5–10% of patients had metastases with un-
known primary. Occasionally a primary neoplasm is not
found elsewhere despite extensive investigations, raising the
possibilitythatthehepaticlesionistheprimarytumour[21].
This might be due to the low sensitivity of currently available
imaging techniques, although this seems increasingly less
likely with advances in technology such as helical computed2 International Journal of Hepatology
tomography (CT), endoscopic ultrasonography (EUS), and
Gallium-68 PET CT.
Histologicalsubtypeshaveaninﬂuenceontreatmentand
survival outcomes. The reported overall survival ranges from
5.2 to 57% with diﬀerent histological subsets of digestive
NETs [7, 20]. A 95% survival at 20 years has been reported
for patients with gastrinoma without liver metastases in
contrast with 15% 10-year survival in the presence of bilobar
hepatic metastases [22]. 5-year survivals of midgut and
hindgut NET decrease by 10–20% and 50–60%, respectively,
in the presence of liver metastases [23–26]. The new WHO
classiﬁcation (2010) emphasizes the importance of grades
G1–3. Tumors with <2 mitosis/10hpf and <3% Ki67 index
are well diﬀerentiated and are labelled as G1 tumors, while
well-diﬀerentiated tumors with 2–20 mitosis/10hpf or 3%–
20% Ki67 index are designated as G2. High immunohisto-
chemical expression of Ki67 is a strong marker of poorly
diﬀerentiatedNETs,andtumorswith>20mitoses/10hpfora
Ki67 >20% are labelled as G3 tumors [3]. Well-diﬀerentiated
G1 tumors tend to be more indolent and are good candidates
for liver-directed therapy, whereas poorly diﬀerentiated G3
neuroendocrine carcinomas (with or without liver metas-
tases) are highly aggressive and patients (even with treated
metastatic disease) have an expected survival time of 6–18
months [27, 28] .T h e s et u m o r sa r en o tp r o p o s e df o rs u r g i c a l
resection and are usually conﬁned to systemic chemotherapy
(commonly Cisplatin and Etoposide combination).
3. Distribution of Hepatic Metastases
The pattern of distribution of liver metastases is an impor-
tant determinant of prognosis [26, 29, 30]. Three diﬀerent
patterns of NEN-LM are identiﬁed that have an impact on
thetherapeuticapproach:TypeI:“restrictedmetastases,”that
is, the metastases are conﬁned to one liver lobe or limited to
two adjacent segments. This pattern is usually seen in 20–
25% of the cases; the metastases are clearly resectable and
can be dealt with by a standard anatomical resection; Type
II: “dominant lesion with bilobar metastases” in which there
is one dominant lesion but with smaller satellites contralat-
erally. Such bilobar patterns occur in 10–15% of the cases;
the metastases may be potentially resectable and can still be
approachedsurgicallywithacombinationofablativetherapy
on the contralateral lobe; Type III: “diﬀuse, multifocal liver
metastases” are found in 60–70% of the cases and surgery
is not a good option for these tumors [31, 32]. Type III
tumorsareclearlyunresectable,andacautiousoptionofliver
transplant may be considered for these tumors. Thus, the
extent of hepatic involvement of metastatic NEN limits the
beneﬁt of surgery in a substantial majority of patients and
standard resection alone is inadequate [33]. Nevertheless, it
isevidentthatTypeINEN-LMareassociatedwithfavourable
outcomes compared to the other two types [10, 30].
4.DiagnosticWork up for Neuroendocrine
LiverMetastases
Combined anatomic and functional imaging studies pro-
vide tumor localization and assessment of posttreatment
outcomes. Our current practice of evaluation is a Triphasic
TriplanarCTscanwith1-2mmslicethickness.Atypicalcon-
trast enhancement in the arterial phase of the scans is char-
acteristic due to the hypervascular nature of these tumors.
However, depending on the tumor type, size, and location,
the portal and parenchymal phases of contrast enhancement
may also be important for improved detection [34–37].
Magneticresonance(MR)imagingiscomplimentaryand
especially helpful in patients unable to receive iodinated con-
trast agents. One study [38] showed that MR imaging can
detect more liver lesions, and a T2-weighted imaging may
detect most lesions when contrast agents cannot be given.
Somatostatin receptor scintigraphy (SRS) has rapidly
evolved as the gold-standard imaging procedure for NEN
expressing somatostatin receptor subtype 2. Indium-labelled
somatostatin analogues have been replaced by Gallium-
labelled analogues that in combination with a PET-CT (68
Ga-DOTATOC PET/CT) increase the diagnostic sensitivity
up to 30% higher than the conventional scanning. Moreover,
SRS has resulted in a change in the clinical management in
33–77% of NEN patients in various studies [31, 39].
Beside the advantage of total-body imaging with the po-
tential of simultaneous visualization of the primary tumour
and metastatic deposits, SRS can possibly identify those pa-
tients who might be candidates for somatostatin receptor-
based radiotherapy [39–41].
Plasma chromogranin A (CgA) is a widely accepted
tumour marker with respect to diagnosis, prognosis, and
monitoring of the treatment [42–45]. Though the sensitivity
of CgA depends upon the NEN type and tumour burden,
patients with NEN-LM tend to have signiﬁcantly higher CgA
concentrations than those without metastases [46]. Addi-
tional assessment of insulin, C-peptide, gastrin, pancreatic
polypeptide, vasoactive intestinal peptide, glucagon, calci-
tonin, and somatostatin should be useful depending on the
tumor functional status, clinical symptoms, and histological
features.
A core needle biopsy and a histological examination with
immunohistochemistry (IHC), Ki-67, and mitotic index of
the primary/metastasis is essential for planning treatment.
Tumour staging predicts the prognosis and tailors the
therapeutic strategy [32, 47] particularly in patients who are
not candidates for complete resection.
5. Liver-DirectedTherapy
No optimal therapeutic strategies exist for treatment of liver
metastases from GEP-NEN, and best strategy for treatment
of NEN-LM is still poorly deﬁned [48, 49]. Moreover, there
is no randomized trial comparing surgery with nonsurgi-
cal treatments like RFA (radiofrequency ablation), TACE
(transarterial chemoembolization), and medical treatment.
In view of the infrequency of these tumours, multicentre
clinical trials are needed in addressing the role of surgery.
5.1. Resection
5.1.1. Does Resection Beneﬁt? Surgery is generally proposed
to all patients with operable well-diﬀerentiated metastasesInternational Journal of Hepatology 3
from digestive NENs regardless of the site of origin [32].
However, most NENs are detected after extensive liver
metastases are present, and, consequently, only 10% to 20%
of patients with NEN-LM are eligible for resection [50, 51].
The beneﬁts of surgical resection for NEN-LM have been
demonstrated in terms of overall survival and quality of life.
Overall survival after hepatic resection has been reported
in 46–86% at 5 years and 35–79% at 10 years in various
series [52]. Complete resection (R0/R1) for both mid- and
hindgut tumors is associated with better long-term survival
[30, 53–56]. In many reported series of patients in whom
hepatic resection was feasible, a median survival time was
not reached during a followup of 27 months [56]u pt o7 8
months [57] compared with 27 months [56] and 17 months
[57] in those with unresectable tumours.
A recent multicenter study evaluating 339 patients who
underwent surgical management of NEN-LM from 1985 to
2009 identiﬁed those who are likely to beneﬁt the most
by liver-directed surgery. It was observed that patients with
hormonally functional NEN who had R0/R1 resection ben-
eﬁted the most from surgery [58]. Another large study [59]
observed that R1 resections, unlike many other cancers, were
not associated with a worse overall survival after liver resec-
tion for NEN-LM.
Resection is associated with a low mortality rate (0–5%)
and an acceptable morbidity (close to 30%), and up to 95%
of patients have shown symptom improvement in one large
surgical series of 170 patients [56].
R0 resection rates have been reportedly between 20 and
57% in various series [31, 55, 56, 60–62]; however, among
patients undergoing complete resection, long-term disease-
free survival is reported in up to only 20 percent of patients
[53, 63].
Such variability of clinical outcomes demands a metic-
ulous case selection, and certain prerequisites should be
considered prior to a resectional surgery [32, 52, 64]: (i)
resectable primary tumor (previously resected or considered
resectable synchronously), (ii) well-diﬀerentiated NEN-LM,
(iii) possibility of R0 resection, (iv) exclusion of nonre-
sectable extrahepatic disease, (v) reasonable performance
status, and (vi) corrected or optimised carcinoid heart dis-
ease prior to aggressive liver surgery.
The presence of local recurrence including abdominal
lymph node involvement is not an absolute contraindication
for surgery if the removal of liver metastases and lymph
nodes and/or the recurrence site(s) is planned [32].
In all cases in which the patients have carcinoid syn-
drome, speciﬁc perioperative treatments with somatostatin
analogues are indicated to prevent intra- and postoperative
carcinoid crisis [65, 66].
5.1.2. Recurrence after Resection and Impact of R0 Resection.
Recurrence after an R0 resection is not uncommon, and 5-
y e a rl o c a lr e c u r r e n c er a t e so fu pt o9 7 %h a v eb e e nr e p o r t e d
even when complete resection has been achieved [53, 55, 67,
68]. Recurrence depends mainly on the initial completeness
of liver resection, and a thorough pre- and intraoperative
assessment of small liver metastases is essential.
In a large series of 170 surgically treated patients, 5-
and 10-year recurrence rate was 84% and 94%, respectively,
with a median time to recurrence of 21 months. Only 44%
of patients had a complete tumour resection in this series
with a 5-year recurrence rate of 76% and a median time to
recurrence of 30 months. In comparison patients who did
notundergoacompleteresectionshoweda5-yearrecurrence
rate of 91% with a median time to recurrence of only 16
months [53].
The prognostic relevance of R0 resection has been point-
ed out by Gomez et al. in their report of 18 resected patients
who showed an overall 5-year recurrence rate of 34%. The
ﬁve-year recurrence was only 10% in patients with tumour-
free resection margins, in contrast to 75% when resection
margins were involved [68]. Thus, an aggressive surgical
approach does beneﬁt irrespective of completeness or R0
status and has an impact on prognosis.
5.1.3. Resection Strategies in Synchronous and Metachronous
Tumors. Unlike most malignancies, resection of the primary
isbeneﬁcialforpatientswithNENsandshouldbeconsidered
in patients who have resectable metastatic disease [69, 70].
However, resection of a small asymptomatic (relatively sta-
ble) primary in the presence of unresectable metastatic dis-
ease is not indicated [69].
In synchronous disease, liver surgery can be performed
either as a one-step or a two-step procedure [32, 55, 71].
NEN-LM may be resected at the same time as the primary
tumorwithlittleadditionalriskifthemetastasesareunilobar
[54, 55]. The main consideration however should be to
performacompleteresectionwithacceptablemorbidityrate.
If major or complex liver resection is required, a two-stage
surgery may be preferable in order to reduce the operative
risk especially in patients with Type II metastases. A two-step
surgery may involve at the ﬁrst step a resection of metastases
of the one lobe in addition to a resection of the primary
and lymph nodes. Contralateral liver volume enhancement
by portal venous embolization is an option with an aim to
induce left liver hypertrophy followed by right hepatectomy
or Lobectomy as a second step. Such an approach can
in selected patients avoid or delay indications for liver
transplantation [71]. For patients with unresectable liver
metastases, a cholecystectomy is recommended to prevent
ischemic complications of the gallbladder subsequent to che-
moembolization and possible gallstones formation during
somatostatin analogue therapy [54].
For metachronous liver metastases, a one-step procedure
can be recommended as a low-risk approach to unilobar
disease (<30% morbidity). For bilobar or diﬀuse liver me-
tastases, a sequential approach including resection with or
without ablative techniques, preoperative portal emboliza-
tion, percutaneous treatments, or intra-arterial chemoem-
bolization may be adopted [32, 72].
Overall, the eﬀectiveness of the resection of unilobar and
bilobar liver metastases depends on the operative techniques
employed as well as the competence of the hepatobiliary sur-
geon. Intraoperative ultrasonography is essential in deﬁning
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smaller lesions missed during a preoperative diagnosis. Re-
sectional surgery should be the ﬁrst option before patient is
considered for liver transplantation due to standard priority
in listing.
5.1.4. Does Debulking Beneﬁt? Several retrospective series
have suggested that selected patients who undergo aggressive
“debulking” of NEN-LM, in which the majority but not
all of the disease is resected, have better quality of life and
longer survival relative to those who do not undergo surgery
[10, 30, 73–77]. Soreide et al. [78] found that patients with
NEN hepatic metastases who underwent surgical debulking
(plannedrepeatoperationsincluded)hadathree-tofourfold
longer median survival time compared with those who did
not. However, complication and mortality rates were high
(33% and 9%, resp.), and the duration of symptom relief in
most cases was 6–24 months.
Incomplete debulking surgery (R2) has limited indica-
tions, yet it can improve the quality of life in selected patients
for whom medical treatment has failed. However, in order to
be eﬃcient, the removal of at least 90% of the tumor volume
is required [54, 56, 79, 80].
Thus, when complete resection of NEN-LM is not fea-
sible or in the presence of unresectable extrahepatic disease,
a tumor debulking strategy should be considered especially
in patients with functional NENs with hormonal symptoms
refractory to other treatments. Debulking can be a strategy
for nonfunctioning NENs with local eﬀects such as abutting
the hepatic hilum (resulting in biliary obstruction) or ob-
structing the colon/duodenum [47, 81].
Acombinationoftechniques,namely,resectionandabla-
tion or resection combined with other liver-directed therapy
should be used to achieve complete tumor response when all
liver disease cannot be resected.
5.2. Local Ablative Techniques. Radiofrequency ablation
(RFA) has become the preferred local-ablative therapy in
most centres, and its use has been shown to be eﬀective in
bothrelievingthesymptomsofNEN-LMandachievinglocal
control of the metastases [32, 82, 83].
Mazzaglia and colleagues reported the largest experience
of ablation in patients with NEN-LM, encompassing a total
of452lesionsin63patientsvia80laparoscopicRFAsessions.
Thirty-six patients were symptomatic from disease, and 94%
experienced symptom relief after ablation for a median
duration of 11 ± 2.3 months after RFA. The procedure-asso-
ciated morbidity was 5%, and there was no 30-day mortality.
Median survival was 3.9 years calculated from the ﬁrst RFA
session with a 2-year survival of 77% [84].
In yet another study of patients with 234 NEN metas-
tases, 34 were treated with RFA. 80% of the patients reported
a complete or signiﬁcant relief from their symptoms, lasting
for an average of 10 months and 41% of the treated patients
showed no evidence of progression [85].
Tumor size poses a signiﬁcant limit on the eﬀectiveness
of RFA. Though ablation may be used repeatedly within the
same metastasis, it is diﬃcult to fully eradicate with certainty
tumors that are >3cm in diameter, and a tumor >5cmin
diameter is considered to be unsuitable for RFA [86].
RFA has been shown to be a relatively low-risk procedure
f o rt r e a t i n gl i v e rt u m o r s[ 87], and while the safety of RFA
makes it an attractive method of treatment, the rate of tumor
recurrence after therapy limits its eﬀectiveness as a single
therapy[86].Arecentstudyreportedprogressiveliverdisease
in 80% of patients with NEN liver metastases treated with
RFA [84].
5.3. Combination Techniques of Resection and Other
Modalities
5.3.1. Resection Combined with Cryoablation. While liver
resection for NEN-LMs provides the best chance of long-
term survival, it is unfortunately not feasible in the majority
of patients given the often widespread presentation of
liver disease. Combining resection with local ablation can
potentially expand the resection criteria and thus help
improve survival [88]. In a recent study, forty patients with
NEN-LMs underwent concomitant hepatic resection and
cryoablationbetween1992 and2010 withamedianfollowup
of 61 months (for alive patients). The median progression-
free survival and overall survival after hepatic resection were
22 and 95 months, respectively. Five-year and 10-year overall
survivalratewas61%and40%,respectively.Whilehistologic
grade was an independent factor associated with overall
survival, presence of extrahepatic disease was associated with
progression-free survival.
It thus appears that concomitant hepatic resection and
cryoablation to achieve tumor debulking is associated with
good survival outcomes in well-selected patients. This recent
report suggested that such an approach may increase the
number of patients with borderline resectable disease under-
going surgical management of advanced NEN-LMs [88].
5.3.2. Resection and Radiofrequency Ablation. Therapy with
RFA alone is associated with higher recurrence rates com-
pared to RFA plus resection, and in patients whose metas-
tases are otherwise unresectable or diﬃcult to access, the
combination of resection and RFA provides the opportunity
to achieve complete tumor removal [89–91].
E l i a se ta l .[ 92] reported an overall survival rate of 84%
at 3 years by incorporating a one-step combined approach of
hepatectomy (for large or contiguous NEN-LMs) along with
intraoperative use of multiple RFAs (for remnant metastases
<2.5cm). A mean of 15 ± 9 NEN-LMs per patient were
surgically removed, and a mean of 12 ± 8 (median of 10)
NEN-LMs per patient were RF ablated.
A combination of RFA along with parenchyma preserv-
ingliverresectionsseemstobethewayforwardwhiledealing
with multiple bilobar liver metastases that are unlikely to be
completely resected by surgery alone.
5.3.3. Resection and Chemoembolization. Chemoemboliza-
tion is indicated for nonresectable multiple bilobar metas-
tases, and in various studies 55%–100% of patients with
malignant NENs treated by hepatic arterial embolization
(HAE)/transarterialchemoembolization(TACE)havesymp-
tomatic improvement and 20%–80% have an objectiveInternational Journal of Hepatology 5
Type I “restricted type” NEN-LM Type II “dominant lesion with bilobar”
NEN-LM
Type III “diﬀuse multifocal” 
NEN-LM
NEN-LM
G1/G2 metastases G3 metastases
Resection
(minor or anatomical)
Surgery contraindicated
Surgery contraindicated
One-step surgery
Major liver resection
± RFA (debulking)
Two-step surgery
(1) Minor liver resection
± RFA, PVE, PVL
(2) Sequential major liver
resection
Nonsurgical treatment
Ablation
TACE
Liver transplant
(selected cases)
Nonsurgical treatment
chemotherapy (cisplatin etoposide)
± targeted therapy
TACE
TAE
Biotherapy (i)
Chemotherapy (ii)
PRRT (iii)
Figure 1: Suggested treatment algorithm for patients with NEN-LM. NEN: neuroendocrine neoplasm; LM: liver metastasis; RFA:
radiofrequency ablation; TACE: transcatheter arterial chemoembolization; TAE: transcatheter arterial embolization; PVE: portal vein
embolization; PVL: portal vein ligation.
response with tumor shrinkage. The mean duration of re-
sponse ranges from 6 to 42 months [93–96].
Advances in major liver resectional surgery has resulted
in further development of multimodal approaches for
NELMs where surgeons and interventional radiologists have
tried to work in multidisciplinary settings to evaluate wheth-
er TACE and surgery can have a synergistic action on overall
outcomes of NELMs. Hepatic resection may be possible
after cytoreduction of the tumor following TACE and other
therapies [97]; however, the data on this subject is sparse.
5.4. Liver Transplantation. In patients with diﬀuse unresec-
table liver metastases or who suﬀer from life-threatening
hormonal disturbances refractory to medical therapy, liver
transplantation may be an option for carefully selected pa-
tients [32].
Primary tumor location has an impact on outcomes of
liver transplantation. While the 5-year survival rate was 68%
in patients with limited hepatic disease and nonduodeno-
pancreatic tumours, it dropped to 12% in the case of hepato-
megaly and primary tumour localized within the duodenum
or pancreas [98, 99].
Majority of patients undergoing orthotopic liver trans-
plantation (OLT) ultimately develop recurrent disease and
reported 5-year recurrence-free survival ranges from 24 to
45% with an overall survival range of 36–57% [100–105].
Mazzaferroetal.couldachievea90%overallsurvivaland
a 77% recurrence-free survival at 5 years by deﬁning speciﬁc
criteria for indication of liver transplant in the setting of
NLM: (a) well-diﬀerentiated NENs (low-grade functioning
or nonfunctioning), (b) a prior curatively resected primary
tumor drained by the portal system, (c) ≤50% metastatic
involvement of the liver, (d) good response or stable disease
for a minimum of 6 months prior to transplantation, and (e)
age ≤ 50 years [106].
An early disease recurrence, a considerable postoperative
mortality, the absence of extensive experience, and lack
of universal indications have precluded orthotopic liver
transplantation as a good option for most patients with
unresectable NEN-LMs [107]. Moreover, limited availability
of donor organs in many regions has been a barrier to the
widespread use of liver transplantation in general. Thus,
the potential beneﬁt of liver transplantation in patients
with malignant NENs needs to be weighed against issues of
perioperativemorbidityandtheethicaldistributionofdonor
organs [32].
A modiﬁed algorithm for the treatment of patients with
metastatic NETs based on ENETS consensus guidelines [32]
is shown in Figure 1.
6. Summary
Surgical resection remains the gold standard especially in
the treatment of well-diﬀerentiated NEN-LMs for symptom
relief and long-term survival. In both synchronous and me-
tachronous tumors, one- and two-step procedures may be
undertaken,dependinguponwhethertheliverdiseaseisuni-
lobar or complex.
Debulking resections are justiﬁed in functioning NEN
and selective nonfunctioning NENs; however, removal of at
least 90% of the tumor volume is necessary.
RFAcanbeusedeﬀectivelyasantitumortreatmentandas
a sole therapy for relieving symptoms in patients with NEN-
LMs, but when combined with resection a better outcome is
anticipated.6 International Journal of Hepatology
Liver transplantation needs to be carefully considered
in speciﬁc liver alone bilobar metastases especially in (low-
grade) well-diﬀerentiated NENs.
Surgical options are complimented by ablative tech-
niques (RFA/cryoablation), nonsurgical liver-directed thera-
pies (HAE/TACE/Transarterial radioembolization—TARE),
and systemic treatment modalities (peptide receptor radio-
therapy, cytotoxic chemotherapy, somatostatin analogues,
and newer molecular-targeted treatments). A multidisci-
plinary team approach is necessary to customize therapy for
each patient with NEN-LM.
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